デフォルト表紙
市場調査レポート
商品コード
1764174

アダリムマブ市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、治療領域別、地域別、競合別、2020年～2030年

Adalimumab Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Therapeutic Area, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
アダリムマブ市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、治療領域別、地域別、競合別、2020年～2030年
出版日: 2025年06月30日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

アダリムマブの世界市場は、2024年に27億2,000万米ドルと評価され、2030年には35億6,000万米ドルに達すると予測され、予測期間のCAGRは4.80%で成長すると予測されています。

腫瘍壊死因子α（TNF-a）を標的とするモノクローナル抗体であるアダリムマブは、関節リウマチ、クローン病、潰瘍性大腸炎、乾癬、強直性脊椎炎などの自己免疫疾患の管理において極めて重要な役割を果たしています。炎症を抑制し、疾患の進行を遅らせる効果が実証されていることから、免疫学において広く採用されている治療薬となっています。同市場の成長には、慢性炎症性疾患の罹患率の上昇、生物学的製剤による治療に対する意識の高まり、特に新興国におけるヘルスケア投資の増加が主に寄与しています。成熟市場では価格圧力が続いているもの、先進治療への世界のアクセスと診断率の上昇が市場の持続的な拡大を支えていると予想されます。

市場概要
予測期間 2026年～2030年
市場規模：2024年 27億2,000万米ドル
市場規模：2030年 35億6,000万米ドル
CAGR：2025年～2030年 4.80%
急成長セグメント 生物製剤
最大市場 北米

市場促進要因

ヘルスケア産業の成長

主な市場課題

生産コストの高さ

主な市場動向

慢性疾患の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のアダリムマブ市場に与える影響

第5章 世界のアダリムマブ市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別（生物製剤、バイオシミラー）
    • 治療領域別（関節リウマチ、乾癬性関節炎、乾癬、クローン病、その他）
    • 地域別
    • 企業別（2024年）
  • 市場マップ

第6章 北米のアダリムマブ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州のアダリムマブ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋のアダリムマブ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米のアダリムマブ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのアダリムマブ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 世界のアダリムマブ市場：SWOT分析

第15章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第16章 競合情勢

  • AbbVie Inc.
  • Pfizer, Inc.
  • Amgen Inc.
  • Novartis AG
  • Torrent Pharmaceuticals Ltd.
  • Cadila Healthcare Limited
  • Boehringer Ingelheim International GmbH
  • Mylan N.V.
  • Hetero Biopharma Ltd
  • Samsung Bioepis Co Ltd.

第17章 戦略的提言

第18章 調査会社について・免責事項

目次
Product Code: 4996

The Global Adalimumab Market was valued at USD 2.72 billion in 2024 and is anticipated to reach USD 3.56 billion by 2030, growing at a CAGR of 4.80% over the forecast period. Adalimumab, a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-a), plays a pivotal role in managing autoimmune conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and ankylosing spondylitis. Its proven efficacy in controlling inflammation and slowing disease progression has made it a widely adopted therapy in immunology. The market's growth is primarily fueled by the rising incidence of chronic inflammatory diseases, greater awareness of biologic treatments, and increased healthcare investment, particularly in emerging economies. Despite ongoing pricing pressures in mature markets, global access to advanced therapies and increased diagnosis rates are expected to support sustained market expansion.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.72 Billion
Market Size 2030USD 3.56 Billion
CAGR 2025-20304.80%
Fastest Growing SegmentBiologics
Largest MarketNorth America

Key Market Drivers

Growth in Healthcare Industry

The expanding global healthcare industry, generating annual revenues exceeding USD 4 trillion, is significantly driving the adalimumab market forward. Pharmaceuticals and biotechnology, accounting for nearly USD 850 billion, represent key contributors to this growth. As healthcare infrastructure improves across developed and emerging regions, diagnoses of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease are becoming more common-boosting demand for adalimumab. Advanced diagnostics and early intervention, made possible by rising investment in healthcare systems, are leading to increased use of targeted biologics. Government support, private sector investment, and broader insurance coverage are also making high-cost treatments more accessible. With global healthcare spending reaching USD 9.8 trillion in 2021, representing over 10% of global GDP, emerging markets are witnessing improved patient access to biologics through expanded hospital networks and reform-driven health systems. As a result, adalimumab continues to benefit from these advancements, cementing its position as a frontline treatment in immunology.

Key Market Challenges

High Cost of Production

A key challenge in the global adalimumab market is the high cost of biologic drug production. The manufacturing of adalimumab, a complex monoclonal antibody, involves intricate biotechnological methods that require substantial investment in specialized infrastructure, skilled personnel, and regulatory compliance. The use of living cells in the development process, combined with tightly controlled manufacturing conditions, contributes to elevated production costs. Critical stages such as cell culture, purification, and formulation are both time-consuming and resource-intensive. Furthermore, risks such as batch failure and the rigorous validation requirements further strain cost efficiency. These high production costs pose a barrier for manufacturers, particularly when attempting to scale or introduce biosimilars in competitive markets.

Key Market Trends

Rising Prevalence of Chronic Diseases

The growing incidence of autoimmune and inflammatory diseases represents a significant trend shaping the adalimumab market. Conditions like rheumatoid arthritis, ulcerative colitis, psoriasis, and Crohn's disease are becoming more prevalent, driven by aging populations, sedentary lifestyles, and environmental triggers. As these chronic conditions often require long-term treatment, demand for reliable and effective biologics continues to rise. Adalimumab, with its broad therapeutic indications and established clinical profile, remains a preferred option for managing chronic inflammation. It was the first fully human monoclonal antibody to receive approval for rheumatoid arthritis and has since proven its safety and efficacy in long-term use. This growing reliance on biologics underscores the sustained role of adalimumab in immunological treatment strategies worldwide.

Key Market Players

  • AbbVie Inc.
  • Pfizer, Inc.
  • Amgen Inc.
  • Novartis AG
  • Torrent Pharmaceuticals Ltd.
  • Cadila Healthcare Limited
  • Boehringer Ingelheim International GmbH
  • Mylan N.V.
  • Hetero Biopharma Ltd
  • Samsung Bioepis Co Ltd.

Report Scope

In this report, the Global Adalimumab Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Adalimumab Market, By Type:

  • Biologics
  • Biosimilars

Adalimumab Market, By Therapeutic Area:

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Psoriasis
  • Crohn's Disease
  • Others

Adalimumab Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Adalimumab Market.

Available Customizations

Global Adalimumab Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Adalimumab Market

5. Global Adalimumab Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Biologics, Biosimilars)
    • 5.2.2. By Therapeutic Area (Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Adalimumab Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Therapeutic Area
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Adalimumab Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Therapeutic Area
    • 6.3.2. Mexico Adalimumab Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Therapeutic Area
    • 6.3.3. Canada Adalimumab Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Therapeutic Area

7. Europe Adalimumab Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Therapeutic Area
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Adalimumab Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Therapeutic Area
    • 7.3.2. Germany Adalimumab Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Therapeutic Area
    • 7.3.3. United Kingdom Adalimumab Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Therapeutic Area
    • 7.3.4. Italy Adalimumab Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Therapeutic Area
    • 7.3.5. Spain Adalimumab Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Therapeutic Area

8. Asia Pacific Adalimumab Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Therapeutic Area
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Adalimumab Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Therapeutic Area
    • 8.3.2. India Adalimumab Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Therapeutic Area
    • 8.3.3. South Korea Adalimumab Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Therapeutic Area
    • 8.3.4. Japan Adalimumab Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Therapeutic Area
    • 8.3.5. Australia Adalimumab Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Therapeutic Area

9. South America Adalimumab Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Therapeutic Area
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Adalimumab Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Therapeutic Area
    • 9.3.2. Argentina Adalimumab Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Therapeutic Area
    • 9.3.3. Colombia Adalimumab Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Therapeutic Area

10. Middle East and Africa Adalimumab Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Therapeutic Area
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Adalimumab Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Therapeutic Area
    • 10.3.2. Saudi Arabia Adalimumab Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Therapeutic Area
    • 10.3.3. UAE Adalimumab Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Therapeutic Area

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Adalimumab Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. AbbVie Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Pfizer, Inc.
  • 16.3. Amgen Inc.
  • 16.4. Novartis AG
  • 16.5. Torrent Pharmaceuticals Ltd.
  • 16.6. Cadila Healthcare Limited
  • 16.7. Boehringer Ingelheim International GmbH
  • 16.8. Mylan N.V.
  • 16.9. Hetero Biopharma Ltd
  • 16.10. Samsung Bioepis Co Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer